At week @ , the proportion of patients with a PGA score of @ or @ remained significantly higher in the @-mg , @-mg , and @-mg guselkumab groups than in the adalimumab group ( @ % , @ % , and @ % , respectively , vs. @ % ) ( P < @ for all comparisons ) .